箕星药业完成2.87亿美元D1轮融资，CEO牟艳萍复旦上海医学院毕业

Core Insights - Corxel Pharmaceuticals Limited (referred to as "Corxel") has successfully completed a Series D financing round, raising a total of $287 million [2] - New investors in this round include SR One, TCGX, Adage Capital Management, RA Capital Management, HBM Healthcare Investments, SymBiosis, Invus, SilverArc Capital, among others, while existing investors RTW Investments and Hengdian Capital also participated, indicating confidence in Corxel's clinical advantages and long-term strategy [2] - The funds raised will primarily be used to advance the development of CX11, an oral small molecule GLP-1 RA currently undergoing a Phase 2 clinical trial in the U.S. for treating obesity and overweight patients, with a Phase 3 trial being conducted in China by a partner [2] - Additional funding will support the development of other cardiovascular and metabolic projects, including pipelines targeting acute ischemic stroke and hypertension [2] Company Overview - Corxel was incubated by RTW in 2019 and is focused on developing innovative therapies for patients with cardiovascular and metabolic diseases [3] - Sandy Mou, the Executive Director and CEO of Corxel, has nearly 30 years of experience in the pharmaceutical and medical device industry, having held management positions in several multinational companies [3] - Mou has a medical degree from Fudan University and an EMBA from China Europe International Business School, with a background in launching significant products across various disease areas [3]